Hematology/Oncology Clinics of North America This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Management of Newly Diagnosed Multiple Myeloma Today, and in the Future
Treatment options have expanded rapidly and widely in the past two decades for patients with multiple myeloma. Triplet novel agent-based induction regimens have been accepted as the standard practice wordwide over the last decade both for transplant-eligible and non-eligible patients. The addition of anti-CD38 monoclonal antibodies as part of quadruplet regimens has led to even deeper and longer-lasting responses. The impressive results shown by the quadruplets havebeen practice-changing where accessible in recent years. Chimeric antigen receptor T cell therapy and bispecific antibodies are being tested in the upfront sett...
Source: Hematology/Oncology Clinics of North America - January 2, 2024 Category: Cancer & Oncology Authors: Anup Joseph Devasia, Guido Sebastian Lancman, Alexander Keith Stewart Source Type: research

Extraordinary Progress in the Treatment of Multiple Myeloma: Is a Cure on the Horizon?
My father, Daniel Bergsagel, reported on the activity of melphalan in the treatment of multiple myeloma (MM) in 1962, and melphalan and prednisone (MP) remained the standard of care for more than 40 years. This frustrated him, and he would tell me that to make progress we needed better drugs, and a better understanding of disease pathogenesis. Now we have both. The last major study to use MP as a control arm (VISTA) reported in 2010 a median progression-free survival (PFS) of 17  months and overall survival (OS) of 44 months. (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - January 2, 2024 Category: Cancer & Oncology Authors: Peter Leif Bergsagel Tags: Preface Source Type: research

Smoldering Multiple Myeloma
Smoldering multiple myeloma (SMM) is an intermediate clinical stage in the spectrum of monoclonal plasma cell disorders. It represents a heterogeneous clinically defined condition in which some patients (approximately 50%) have monoclonal gammopathy of undetermined significance (premalignancy), and some (approximately 50%) have multiple myeloma (biologic malignancy). Using specific prognostic factors, patients with SMM, in whom malignant transformation has already likely occurred, can be identified. These patients are considered to have high-risk SMM. Patients with newly diagnosed high-risk SMM are candidates for early int...
Source: Hematology/Oncology Clinics of North America - December 28, 2023 Category: Cancer & Oncology Authors: S. Vincent Rajkumar, P. Leif Bergsagel, Shaji Kumar Source Type: research

Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma
Chimeric antigen receptor T  cells (CARTs) represent another powerful way to leverage the immune system to fight malignancy. Indeed, in multiple myeloma, the high response rate and duration of response to B cell maturation antigen-targeted therapies in later lines of disease has led to 2 Food and Drug Administration (FDA) dru g approvals and opened the door to the development of this drug class. This review aims to provide an update on the 2 FDA-approved products, summarize the data for the most promising next-generation multiple myeloma CARTs, and outline current challenges in the field and potential solutions. (Source: ...
Source: Hematology/Oncology Clinics of North America - December 28, 2023 Category: Cancer & Oncology Authors: Zainul S. Hasanali, Beatrice Razzo, Sandra P. Susanibar-Adaniya, Alfred L. Garfall, Edward A. Stadtmauer, Adam D. Cohen Source Type: research

Monoclonal Antibodies in the Treatment of Multiple Myeloma
The incorporation of monoclonal antibodies into backbone regimens has substantially improved the clinical outcomes of patients with newly diagnosed and relapsed/refractory multiple myeloma (MM). Although the SLAMF7-targeting antibody elotuzumab has no single- agent activity, there is clinical synergy between elotuzumab and immunomodulatory drugs in patients with relapsed/refractory disease. Daratumumab and isatuximab are CD38-targeting antibodies which have single-agent activity and a favorable safety profile, which make these agents an attractive component of combination regimens. Monoclonal antibodies may cause infusion-...
Source: Hematology/Oncology Clinics of North America - December 26, 2023 Category: Cancer & Oncology Authors: Niels W.C.J. van de Donk, Sonja Zweegman Source Type: research

Is There Still a Role for Stem Cell Transplantation in Multiple Myeloma?
No therapy in multiple myeloma has been as extensively investigated as stem cell transplantation following high-dose chemotherapy. A search of the national library of medicine in February 2023 revealed over 27,000 publications covering stem cell transplantation. No other treatment for multiple myeloma has been so vigorously investigated. However, given the rapid advances seen in the treatment of multiple myeloma, it is legitimate to ask whether the technique first introduced in 1983 by Thomas McIlwain still has relevance. In 1984,Barlogie introduced infusional vincristine, doxorubicin, and dexamethasone and in 1986 publish...
Source: Hematology/Oncology Clinics of North America - December 26, 2023 Category: Cancer & Oncology Authors: Morie A. Gertz Source Type: research

Global Oncology: Disparities, Outcomes and Innovations Around the Globe
HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - November 17, 2023 Category: Cancer & Oncology Authors: Mary D. Chamberlin, Narjust Florez Source Type: research

Copyright
ELSEVIER (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - November 17, 2023 Category: Cancer & Oncology Source Type: research

Contributors
GEORGE P. CANELLOS, MD (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - November 17, 2023 Category: Cancer & Oncology Source Type: research

Contents
Charles R. Thomas Jr. (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - November 17, 2023 Category: Cancer & Oncology Source Type: research

Forthcoming Issues
New Developments in Myeloma (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - November 17, 2023 Category: Cancer & Oncology Source Type: research

Erratum
In the December 2023 Hematology/Oncology Clinics (Volume 37, Issue 6) article, “Chimeric Antigen Receptor T Cells in Hodgkin and T-Cell Lymphomas,” support provided by Stand Up to Cancer Meg Vosburg T Cell Lymphoma Dream Team Grant should have been cited in the Acknowledgments on page 1121. (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - November 17, 2023 Category: Cancer & Oncology Source Type: research

CAR T-Cell
HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - October 11, 2023 Category: Cancer & Oncology Authors: Caron A. Jacobson, Parth S. Shah Source Type: research

Copyright
ELSEVIER (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - October 11, 2023 Category: Cancer & Oncology Source Type: research

Contributors
GEORGE P. CANELLOS, MD (Source: Hematology/Oncology Clinics of North America)
Source: Hematology/Oncology Clinics of North America - October 11, 2023 Category: Cancer & Oncology Source Type: research